IMMUNABS
3.8.2022 16:02:08 CEST | Business Wire | Press release
ImmunAbs Inc. (www.immunabs.com ) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States.
ImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, when out of regulation, cause various autoimmune diseases, including but not limited to paroxysmal nocturnal hemoglobinuria (PNH). The complement inhibitors drug market showed its growth potential by achieving an average annual growth rate of 20.7% and a market size of USD $ 5.1 billion in 2020 and is expected to grow to USD $19 billion by 2027.
Paroxysmal nocturnal hemoglobinuria is one example of complement-mediated autoimmune diseases where the membrane proteins protecting the red blood cells from complement activation are lost due to mutations, which results in red blood cells being destructed by the complements. Due to insufficient inhibition of complements shown by currently approved complement inhibitors, SolirisⓇ and UltomirisⓇ , patients who receive these drugs still suffer from the residual symptoms of PNH, which include anaemia, fatigue, and decreased productivity at work.
ImmunAbs’ new complement therapeutic IM-101 targets the safest and most potent component of the complement system, complement C5. IM-101 has been shown to completely inhibit complement activation, and thus is expected to alleviate the symptoms that persist with the standard of care. ImmunAbs will initiate a phase 2a clinical trial in the United States in 2024.
“This is a historical milestone for ImmunAbs.” said Dr. DongJo Kim, the company’s CEO. “We are delighted to see IM-101’s efficacy in humans which has been proven in our ex vivo study. We hope that our IM-101 will reach patients who may suffer from symptoms that persist due to insufficient complement inhibition by the current treatments.”
About ImmunAbs Inc.
ImmunAbs Inc. was established in 2017 by experts of global standard antibody therapeutics development. The vision is "Hope for Patients, Dreams for All." Currently, ImmunAbs has several antibody therapeutics in global standard development for autoimmune diseases, diabetic retinopathy, and metabolic syndrome. ImmunAbs successfully raised KRW 18.1 billion from Seed to series A funding in 2021 and got a non-clinical study national grant for developing IM-101 from Korea Drug Development Fund in November last year.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005380/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons enters into €500 million SACE-backed term loan facility28.7.2026 13:30:00 CEST | Press release
Bending Spoons S.p.A. (NASDAQ: BSP) announced today that it has entered into a new €500 million medium-long-term financing provided by HSBC Continental Europe (acting as Sole Coordinator and MLA), Intesa Sanpaolo S.p.A. (acting as SACE Agent and MLA), and BPER Banca Corporate & Investment Banking (acting as Structuring Advisor and MLA). The facility, which matures in March 2031, benefits from a guarantee provided by SACE, in advancement of SACE’s mission to support the international growth of Italian businesses. Together with €495 million of additional term loan A financing and a €490 million increase in commitments under Bending Spoons’ revolving credit facility, the transaction brings the aggregate amount of new and expanded facilities agreed by Bending Spoons from the beginning of the second quarter to €1.49 billion. Both the term loan A financing and the additional revolving credit facility commitments are available for general corporate purposes and acquisitions, with each of the
Promega Achieves 100% Renewable Electricity Across Global Operations28.7.2026 13:00:00 CEST | Press release
Sustainability accomplishments announced in life sciences company's 2026 Corporate Responsibility Report Promega Corporation today released its 2026 Corporate Responsibility Report, detailing significant environmental and social progress across its global operations. The report marks three milestones for the company: achievement of 100% renewable electricity across all global operations, the completion of a comprehensive value chain emissions inventory and validation of near-term emissions reduction targets by the Science Based Targets initiative (SBTi). “Our 100% renewable electricity reflects years of deliberate investment, from solar arrays on the Madison campus to renewable partnerships in the communities where we operate,” says Corey Meek, Promega Global Sustainability Manager. “Looking forward, we will continue working to strategically reduce the environmental impact of our global business.” Promega recently completed its first comprehensive greenhouse gas inventory across its gl
Lenovo Powers Esports World Cup 2026 as a Founding Partner28.7.2026 11:00:00 CEST | Press release
Lenovo™ joins EWC 2026 as a Global Partner with expanded integration across competition technology at the world’s largest esports eventLenovo Legion™ desktop PCs and monitors will equip players, broadcast operations, training facilities, and festival experiences throughout Paris this summerFans can experience the latest Legion innovations, including the Legion Pro Rollable Concept, during the seven-week competition The Esports Foundation (EF) and Lenovo today announced an expanded partnership, with Lenovo becoming a Global Partner of the Esports World Cup 2026 (EWC) and powering the world’s largest esports event with its high-performance Legion gaming devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712251027/en/ The EWC 2026 will be bringing the world’s largest esports event to Paris for the first time, welcoming more than 2,000 players, 200 esports teams and fans from over 100 countries between July 6 and August
Ten Finalists Announced for the Reply AI Film Festival, the International Competition Bringing Together Cinema and Artificial Intelligence28.7.2026 10:00:00 CEST | Press release
The jury, chaired by Gabriele Salvatores, will announce the winners in Venice on Sunday, 6 September. The Reply AI Film Festival returns for its third edition, reaffirming its role as a meeting point for cinema, creativity and artificial intelligence. The international competition created by Reply – open to creatives experimenting with new AI technologies and tools in the production of short films – has announced its ten finalists. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728146486/en/ The international competition created by Reply – open to creatives experimenting with new AI technologies and tools in the production of short films – has announced its ten finalists. The festival will take place in Veniceduring the days of the 83rd Venice International Film Festival of La Biennale di Venezia. Selected from more than 3,000 short films submitted from 76 countries, the finalist works will take centre stage at the awards
USHIO Industry & Entertainment Announces Trademark Licensing Agreement for OSRAM-Branded Professional Technical Lighting Products28.7.2026 08:30:00 CEST | Press release
Agreement ensures continuity for customers while supporting USHIO Industry & Entertainment's business strategy USHIO Industry & Entertainment (USHIO INE) today announced the signing of a trademark licensing agreement with ams OSRAM, that enables the company to continue offering designated professional technical lighting products under the trusted OSRAM product brand. The agreement marks an important milestone following USHIO's acquisition of the former OSRAM Entertainment & Industry business and reinforces the company's commitment to ensuring continuity for customers, products and long-standing partnerships worldwide. For customers, the agreement provides continuity for professional technical lighting products that have earned a strong reputation across entertainment, cinema, industrial and other specialty lighting applications. These products will continue to be supported by USHIO Industry & Entertainment's global organization, technical expertise and customer service. "The signing of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom